 Translocation (8;21)/AML1-ETO is considered a favorable cytogenetic abnormality in acute myeloid leukemia (AML).     ///    The therapeutic benefit of tyrosine-kinase inhibitor (TKI) was estimated by quantitative analysis of AML1-ETO and the patient's clinical impression.     ///    [Treatment with a tyrosine-kinase inhibitor of for c-KIT mutation and AML1-ETO double positive refractory acute myeloid leukemia]..     ///    "However, patients with refractory AML associated KIT mutations in AML1-ETO should not be considered for TKI monotherapy.. "    ///    "However, the outcomes associated with KIT mutations in AML1-ETO have not been elucidated. "